KOLON LIFE SCIENCE Inc. Q3 profit from the main business KRW 3.6 billion, down 80.9% from a year earlier
KAI summary · Not investment advice
Kolon Life Science sold KRW 58.0 billion worth in Q3 and earned KRW 3.6 billion from its main business, down 80.9% from the same period last year.
Operating profit · 3 months
KRW 3.6 billion
Key facts
- Revenue (3 months)
- KRW 58.0 billion
- Net income (3 months)
- KRW 9.9 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 66.5 billion
- Revenue (year to date)
- KRW 158.2 billion
- Operating profit (prior-year 3 months)
- KRW 18.9 billion
- Operating profit (year to date)
- KRW 5.7 billion
- Net income (prior-year 3 months)
- KRW 25.5 billion
- Net income (year to date)
- KRW 28.6 billion
Commentary
AI commentary · Not investment advice
What happened
Kolon Life Science filed its quarterly report for the 3rd quarter of 2026, on a consolidated basis. Sales for the latest 3 months were KRW 57.98 billion. That is 12.8% lower than the same 3 months a year earlier.
In the company's terms
Operating profit (profit from the core business) for the 3 months was KRW 3.60 billion, down 80.9% from a year earlier. Net income (the final profit after taxes and other costs) was KRW 9.94 billion, down 61.1%.
What changes for shareholders
For the year so far, from January 1 to September 30, sales were KRW 158.23 billion. Operating profit was KRW 5.74 billion. Net income was KRW 28.61 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist